Faculty of Allied Health Sciences, Burapha University
Mueang, Changwat Chon Buri, 20131, Thailand
NCT Number: NCT06195813
Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.
Looking for future studies?
Notify Me18 year–59 year
All sexes
Interventional
Phase 2
Mueang, Changwat Chon Buri, 20131, Thailand
The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Asparagus capsule is categorized as dietary supplement.
Placebo capsule is categorized as other.
Time frame: Day 0 and end of 12 weeks
Level of body fat was measured in percentage unit
Time frame: Day 0 and end of 12 weeks
Level of fat mass was measured in kilogram unit
Time frame: Day 0 and end of 12 weeks
Level of fat distribution was measured by ratio of waist (centimeter) to hip (centimeter)
Time frame: Day 0 and end of 12 weeks
Concentration of blood glucose was measured in serum in mmol/L unit
Time frame: Day 0 and end of 12 weeks
Concentration of blood insulin was measured in serum in uU/mL (microunit/milliliter) unit
Time frame: Day 0 and end of 12 weeks
Concentrations of total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured in serum in mg/dL unit
Time frame: Day 0 and end of 12 weeks
Concentration of blood malondialdehyde was measured in plasma in uM (micromolar) unit
Time frame: Day 0 and end of 12 weeks
Concentration of blood protein carbonyl was measured in plasma in nmol/mg protein unit
Time frame: At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption
Concentrations of blood glucose were measured before and after glucose consumption at 75 g/100 ml in mg/dL unit
Burapha University
Other
Effects of Asparagus Capsule Consumption on Blood Sugar and Lipids and Oxidative Stress in Overweight and Obese Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.